Catalyst Pharmaceuticals

Agios Pharmaceuticals

Reata Pharmaceuticals

Ultragenyx Pharmaceutical

Amicus Therapeutics

Stoke Therapeutics

Ovid Therapeutics

Larimar Therapeutics

USA Rare Earth, Inc.

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 5.98% of float, squeeze risk: LOW

1164 PubMed publications found for Catalyst

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

Deep eutectic solvents in pharmaceutical applications: A review.

Perillaldehyde-derived chromeno-dipyrimidines as multi-target-directed ligands: in vitro anticholinesterase and in vivo anti-inflammatory activities supported by molecular modeling.

Green synthesis and biological evaluation of novel thio-/seleno-imidazo[1,2-a]pyridine derivatives as novel and potent colchicine-site tubulin inhibitors.

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

Dilution score: 10/100 (LOW), 999.0 months cash

1162 PubMed publications found for Catalyst

Screening for high-risk drinking and alcohol use disorder: update of the 2023 national clinical practice guideline.

Short interest: 6.78% of float, squeeze risk: MODERATE

1160 PubMed publications found for Catalyst

Timing of DOAC Initiation After Atrial Fibrillation-Related Acute Ischemic Stroke: A Unified Protocol Harmonizing Clinical Safety and Imaging-Based Precision in the Post-CATALYST Era.

Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial.

SW convergence: 36/100 (Bearish Convergence), 1 bullish / 1 bearish signals

1157 PubMed publications found for Catalyst

Data-informed optimization of CAR T-cell therapy long-term follow-up.

Short interest: 6.8% of float, squeeze risk: MODERATE

Short interest: 7.36% of float, squeeze risk: MODERATE

1156 PubMed publications found for Catalyst

Gradient Copolymers: A Complex Comonomer Incorporation Reality behind the Perfect Ideal.

Short interest: 7.42% of float, squeeze risk: MODERATE

1155 PubMed publications found for Catalyst

SW convergence: 36/100 (Bearish Convergence), 2 bullish / 2 bearish signals

1154 PubMed publications found for Catalyst

1153 PubMed publications found for Catalyst

Building Public Health Data Dashboards: Tutorial Playbook.

<article class="bts-verified-summary" data-ticker="CPRX">
<p>Catalyst Pharmaceuticals (CPRX) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>No Form 4 insider filings for CPRX were recorded at the SEC in the past 30 days<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Catalyst+Pharmaceuticals%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">SEC EDGAR · 0001369568 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22CPRX%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001369568

Catalyst Pharmaceuticals (CPRX) — BioTechSigns Verified Summary

Catalyst Pharmaceuticals (CPRX) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[1].

No Form 4 insider filings for CPRX were recorded at the SEC in the past 30 days[2].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Catalyst+Pharmaceuticals%22&aggFilters=status%3Arec%2Cact
[2] SEC EDGAR, 0001369568. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22CPRX%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

The goal of this study is to collect additional information on the safety of long-term treatment with AGAMREE® and to explore long-term clinical impact of AGAMREE® on quality of life, as assessed by standardized patient-reported outcome measures (QoL questionnaires) in male patients aged 2 years and older with Duchenne muscular dystrophy (DMD).